Anti-interleukin-6 Antibody Clazakizumab in Antibody-mediated Kidney Transplant Rejection: Effect on Donor-derived Cell-free DNA and C-X-C Motif Chemokine Ligand 10
暂无分享,去创建一个
S. Casas | K. Budde | P. Halloran | T. Viard | B. Jilma | G. Böhmig | F. Eskandary | S. Haindl | J. Mühlbacher | Konstantin Doberer | Katharina A Mayer | K. Doberer
[1] A. Heinzel,et al. Levels of donor‐derived cell‐free DNA and chemokines in BK polyomavirus‐associated nephropathy , 2022, Clinical transplantation.
[2] M. Rabinowitz,et al. Combining Donor-derived Cell-free DNA Fraction and Quantity to Detect Kidney Transplant Rejection Using Molecular Diagnoses and Histology as Confirmation , 2022, Transplantation.
[3] D. Brennan,et al. Donor Derived Cell Free DNA in Kidney Transplantation: The Circa 2020–2021 Update , 2022, Transplant International.
[4] K. Budde,et al. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials , 2022, Expert opinion on emerging drugs.
[5] M. Haas,et al. Use of a donor‐derived cell‐free DNA assay to monitor treatment response in pediatric renal transplant recipients with allograft rejection , 2022, Pediatric transplantation.
[6] M. Haas,et al. Evaluation of Clazakizumab (Anti–Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts , 2022, Kidney international reports.
[7] Z. Demko,et al. The Trifecta Study: Comparing Plasma Levels of Donor-derived Cell-Free DNA with the Molecular Phenotype of Kidney Transplant Biopsies , 2022, Journal of the American Society of Nephrology : JASN.
[8] L. Bu,et al. Validation and clinical outcome in assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study. , 2021, Kidney international.
[9] K. Budde,et al. Absolute or Relative Quantification of Donor-derived Cell-free DNA in Kidney Transplant Recipients: Case Series , 2021, Transplantation direct.
[10] S. Casas,et al. Diagnostic value of donor‐derived cell‐free DNA to predict antibody‐mediated rejection in donor‐specific antibody‐positive renal allograft recipients , 2021, Transplant international : official journal of the European Society for Organ Transplantation.
[11] K. Budde,et al. Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. , 2021, Clinical immunology.
[12] P. Halloran,et al. Correlation of Donor-derived Cell-free DNA With Histology and Molecular Diagnoses of Kidney Transplant Biopsies , 2021, Transplantation.
[13] P. Walson,et al. Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury , 2021, Nature Reviews Nephrology.
[14] K. Budde,et al. Exploring the Complexity of Death-Censored Kidney Allograft Failure , 2021, Journal of the American Society of Nephrology : JASN.
[15] D. Brennan,et al. Dynamic Response of Donor-Derived Cell-Free DNA Following Treatment of Acute Rejection in Kidney Allografts. , 2021, Kidney360.
[16] K. Budde,et al. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. , 2020, Journal of the American Society of Nephrology : JASN.
[17] D. Brennan,et al. Donor-derived Cell-free DNA and the Prediction of BK Virus-associated Nephropathy , 2020, Transplantation direct.
[18] D. Wishart,et al. Validity and utility of urinary CXCL10/Cr immune monitoring in pediatric kidney transplant recipients , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[19] P. Marquet,et al. Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection , 2020, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[20] H. Haslacher,et al. Non-invasive Chemokine Detection: Improved Prediction of Antibody-Mediated Rejection in Donor-Specific Antibody-Positive Renal Allograft Recipients , 2020, Frontiers in Medicine.
[21] K. Hedman,et al. Longitudinal assessment of the CXCL10 blood and urine concentration in kidney transplant recipients with BK polyomavirus replication—a retrospective study , 2020, Transplant international : official journal of the European Society for Organ Transplantation.
[22] S. Chadban,et al. Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group , 2019, Transplantation.
[23] T. Friede,et al. Absolute quantification of donor‐derived cell‐free DNA as a marker of rejection and graft injury in kidney transplantation: Results from a prospective observational study , 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[24] P. Halloran,et al. The therapeutic challenge of late antibody‐mediated kidney allograft rejection , 2019, Transplant international : official journal of the European Society for Organ Transplantation.
[25] P. Nickerson,et al. Multicentre randomised controlled trial protocol of urine CXCL10 monitoring strategy in kidney transplant recipients , 2019, BMJ Open.
[26] K. Budde,et al. Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial , 2019, Trials.
[27] A. Loupy,et al. Antibody-Mediated Rejection of Solid-Organ Allografts. , 2018, The New England journal of medicine.
[28] J. Sninsky,et al. Donor-derived Cell-free DNA Identifies Antibody-mediated Rejection in Donor Specific Antibody Positive Kidney Transplant Recipients , 2018, Transplantation direct.
[29] J. Pascual,et al. Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double‐blind clinical trial , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[30] M. Stegall,et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody‐mediated rejection, and prospects for integrative endpoints for next‐generation clinical trials , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[31] M. Posch,et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. , 2017, Journal of the American Society of Nephrology : JASN.
[32] M. Naesens,et al. Precision Transplant Medicine: Biomarkers to the Rescue. , 2017, Journal of the American Society of Nephrology : JASN.
[33] P. Nickerson,et al. Urinary CXCL10 Chemokine Is Associated With Alloimmune and Virus Compartment-Specific Renal Allograft Inflammation , 2017, Transplantation.
[34] K. Budde,et al. Urinary miR‐155‐5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation , 2017, British journal of clinical pharmacology.
[35] M. Haas,et al. Assessment of Tocilizumab (Anti–Interleukin‐6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody‐Mediated Rejection and Transplant Glomerulopathy in HLA‐Sensitized Renal Allograft Recipients , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[36] J. Sninsky,et al. Cell-Free DNA and Active Rejection in Kidney Allografts. , 2017, Journal of the American Society of Nephrology : JASN.
[37] P. Halloran,et al. Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes. , 2017, JCI insight.
[38] D. Brennan,et al. Real Time Central Assessment of Kidney Transplant Indication Biopsies by Microarrays: The INTERCOMEX Study , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[39] U. Christians,et al. Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation , 2016, Therapeutic drug monitoring.
[40] F. Terzi,et al. Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection. , 2015, Journal of the American Society of Nephrology : JASN.
[41] E. Schwaiger,et al. Complement Component C3 Activation: The Leading Cause of the Prozone Phenomenon Affecting HLA Antibody Detection on Single-Antigen Beads , 2014, Transplantation.
[42] A. Kirk,et al. Urinary Chemokines CXCL9 and CXCL10 Are Noninvasive Markers of Renal Allograft Rejection and BK Viral Infection , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[43] P. Nickerson,et al. Urinary CXCL9 and CXCL10 Levels Correlate with the Extent of Subclinical Tubulitis , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[44] F. Thaiss,et al. Compartment-specific expression and function of the chemokine IP-10/CXCL10 in a model of renal endothelial microvascular injury. , 2006, Journal of the American Society of Nephrology : JASN.